Research Recommendations For ADMA Biologics Inc. (ADMA): Here is What You Should Know

0
5
REV
REV

ADMA Biologics Inc. (NASDAQ:ADMA) saw an upside of 3.82% to close Tuesday at $3.53 after adding $0.13 on the day. The 5-day average trading volume is 2,855,220 shares of the company’s common stock. It has gained $3.57 in the past week and touched a new high 2 times within the past 5 days. An average of 2,551,445 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,647,532.

ADMA’s 1-month performance is -4.34% or -$0.12 on its low of $3.26 reached on 01/20/23. The company’s shares have touched a 52-week low of $1.30 and high of $3.98, with the stock’s rally to the 52-week high happening on 01/03/23. YTD, ADMA has lost -9.02% or -$0.35 and has reached a new high 1 time. However, the current price is down -11.31% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Valuation Metrics

ADMA stock has a beta of 0.88. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 5.52 while the price-to-book (PB) in the most recent quarter is 6.92.

ADMA Biologics Inc.’s quick ratio for the period ended June 29 was 1.40, with the current ratio over the same period at 5.00. As well, the company’s long term debt to equity for the quarter ending June 29 was 1.41, while the total debt to equity was 1.41.. In terms of profitability, the gross margin trailing 12 months is 18.90%. The firm’s gross profit as reported stood at $1.17 million against revenue of $80.94 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -18.86% to -$14.9 million, while revenue of -$13.76 million was 7.65% off the previous quarter. Analysts expected ADMA to announce -$0.08 per share in earnings in its latest quarter, but it posted -$0.07, representing a 12.50% surprise. EBITDA for the quarter stood at more than -$6.51 million. ADMA stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 200.17 million, with total debt at $151.26 million. Shareholders hold equity totaling $196.78 million.

Let’s look briefly at ADMA Biologics Inc. (ADMA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 51.80% to suggest the stock is trending Neutral, with historical volatility in this time period at 64.63%.

The stock’s 5-day moving average is $3.41, reflecting a +3.22% or $0.11 change from its current price. ADMA is currently trading -7.11% above its 20-day SMA, +33.71% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +42.91% and SMA200 by+72.20%.

Stochastic %K and %D was 32.11% and 21.56% and the average true range (ATR) pointed at 0.19. The RSI (14) points at 51.33%, while the 14-day stochastic is at 43.55% with the period’s ATR at 0.19. The stock’s 9-day MACD Oscillator is pointing at 0.06 and -0.01 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for ADMA Biologics Inc. (NASDAQ: ADMA), Mizuho launched coverage with a Buy rating.

LEAVE A REPLY

Please enter your comment!
Please enter your name here